{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:09:59Z","timestamp":1778861399676,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["2018-139"],"award-info":[{"award-number":["2018-139"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgar.2021.01.012","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T10:47:36Z","timestamp":1612349256000},"page":"311-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours"],"prefix":"10.1016","volume":"24","author":[{"given":"Thuy","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Amiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Netzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"L\u2019Yavanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Ohayon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Valin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrine","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Kreplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Pialoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Todesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.01.012_bib0005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s15010-016-0975-y","article-title":"Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000\u20132016: a systematic review and meta-analysis","volume":"45","author":"Ghisla","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2021.01.012_bib0010","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2021.01.012_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/QAI.0000000000002099","article-title":"Shared HCV transmission networks among HIV-1-positive and HIV-1-negative men having sex with men by ultradeep sequencing","volume":"82","author":"Nguyen","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2021.01.012_bib0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","volume":"23","author":"Wyles","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2021.01.012_bib0025","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jgar.2021.01.012_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jgar.2021.01.012_bib0035","unstructured":"American Association for the Study of Liver Diseases (AASLD). https:\/\/www.hcvguidelines.org\/evaluate\/resistance [Accessed 27 April 2020]."},{"key":"10.1016\/j.jgar.2021.01.012_bib0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","article-title":"HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe","volume":"66","author":"Ingiliz","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jgar.2021.01.012_bib0045","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jgar.2021.01.012_bib0050","article-title":"World-wide prevalence of substitutions in HCV genome associated with resistance to direct-acting antiviral agents","author":"Liu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jgar.2021.01.012_bib0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jgar.2021.01.012_bib0060","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jgar.2021.01.012_bib0065","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.012_bib0070","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.012_bib0075","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2021.01.012_bib0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jgar.2021.01.012_bib0085","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1\u20136 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jgar.2021.01.012_bib0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijantimicag.2018.09.010","article-title":"Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing","volume":"53","author":"Nguyen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.01.012_bib0095","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2147\/IDR.S172226","article-title":"Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant","volume":"11","author":"Perales","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2021.01.012_bib0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:23:16Z","timestamp":1778858596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":20,"alternative-id":["S2213716521000242"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.01.012","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}